RenovoRx (RNXT)
NASDAQ:RNXT
Want to see RNXT full AI Analyst Report?
Top Page
RenovoRx
(NASDAQ:RNXT)
Select Model
Select Model
Rating:50Neutral
Price Target:
$0.78
▼(-21.70% Downside)
Action:Reiterated
Date:05/19/26
The score is held back primarily by weak financial performance (large losses and sustained cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting these are constructive earnings-call signals—reiterated revenue guidance, strong gross margins, expanding commercial footprint, and extended cash runway—though valuation remains difficult to support given ongoing losses and no stated dividend yield.
Positive Factors
High Gross Margins
Sustained high gross margins (TTM ~79%, Q1 85.1%) indicate attractive unit economics for the RenovoCath device. Durable margin strength supports scalable revenue conversion, cushions operating losses as volumes rise, and reduces the revenue threshold needed for breakeven.
Negative Factors
Persistent Cash Burn
Consistent multi-million dollar operating cash burn reflects a cost structure well ahead of revenue scale. Over months this forces reliance on external funding, risks dilutive financings, and constrains strategic optionality if commercial conversion or trial timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained high gross margins (TTM ~79%, Q1 85.1%) indicate attractive unit economics for the RenovoCath device. Durable margin strength supports scalable revenue conversion, cushions operating losses as volumes rise, and reduces the revenue threshold needed for breakeven.
Read all positive factors
RenovoRx (RNXT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$39.71M
Dividend YieldN/A
Average Volume (3M)288.82K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue Growth520.42%
EPS Growth16.12%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding45,052,708
10 Day Avg. Volume236,040
30 Day Avg. Volume288,821
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)5.47
Price to Sales (P/S)26.43
P/FCF Ratio-2.70
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue13.79
Enterprise Value/Gross Profit17.52
Enterprise Value/Ebitda-1.60
Forecast
1Y Price Target
$6.88Price Target Upside587.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$3.25M
RenovoRx Business Overview & Revenue Model
Company Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and Reno...
How the Company Makes Money
null...
RenovoRx Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 13, 2026
Earnings Call Sentiment Positive
The call presented strong commercial momentum and meaningful operational milestones: record quarterly revenue with very high gross margins, rapid expansion of active centers and a sizable prospect pipeline, near-completion of the pivotal Phase III trial, and a successful $10M private placement providing runway into H2 2027. Offsetting factors include still-modest absolute revenue, sizable operating expenses (R&D $1.2M; SG&A ~$2.7M), remaining trial and event targets to achieve, and timing/convertibility risk of pipeline centers. Overall the positive execution on commercial scaling, healthy margins, and a reinforced balance sheet materially outweigh the near-term risks described.Positive Updates
Record Quarterly Revenue and Rapid Growth
Q1 2026 revenue of $563,000 was the company's highest quarterly revenue to date, representing ~136% quarter-over-quarter growth vs Q4 2025 ($238,000) and ~186% year-over-year growth vs Q1 2025 ($197,000). Q1 2026 revenue accounts for approximately 51% of total 2025 revenue ($1.1M).
Negative Updates
Significant Operating Expenses
Q1 2026 R&D expenses were $1.2M and selling, general & administrative expenses were approximately $2.7M. Management noted SG&A was slightly above projections while R&D was below expectations, reflecting timing variances but leaving sizable near-term operating burn.
Read all updates
Q1-2026 Updates
Positive
Negative
Record Quarterly Revenue and Rapid Growth
Q1 2026 revenue of $563,000 was the company's highest quarterly revenue to date, representing ~136% quarter-over-quarter growth vs Q4 2025 ($238,000) and ~186% year-over-year growth vs Q1 2025 ($197,000). Q1 2026 revenue accounts for approximately 51% of total 2025 revenue ($1.1M).
Read all positive updates
Company Guidance
RenovoRx reiterated full-year 2026 revenue guidance of $3.0–$4.0 million and said Q2 revenue is expected to exceed Q1 2026 ($563,000), which was the company’s highest quarter to date — up ~136% sequentially from Q4 2025 ($238,000) and above Q1 2025 ($197,000) — with Q1 2026 alone representing ~51% of 2025 revenue ($1.1M); Q1 gross profit was $479,000 (gross margin 85.1%), R&D spend was $1.2M (including a $141,000 TIGeR‑PaC study receipt), SG&A was ~ $2.7M, and the company closed an oversubscribed private placement raising ~$10M leaving cash and equivalents of ~$12.4M as of March 31, 2026 (runway into 2H 2027 as it works toward cash‑flow positive); commercial metrics include 16 active centers (up from 8 at year‑end 2025 and 5 at start of 2025), 32 additional centers in evaluation for a total pipeline of 48 (a ~4x near‑term pipeline vs Q1 2025) and a target of 36 active centers by year‑end, while the Phase III TIGeR‑PaC trial has randomized 106 of 114 patients (~93%) with 12 in induction, 74 of 86 required events observed, enrollment expected to close by end of June 2026, and final data anticipated mid‑to‑late 2027.RenovoRx Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
57
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.49M | 1.12M | 43.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.17M | 796.00K | 43.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.87M | -12.51M | -10.97M | -11.39M | -9.94M | -5.48M |
| Net Income | -12.27M | -11.17M | -8.81M | -10.23M | -9.89M | -6.32M |
Balance Sheet | ||||||
| Total Assets | 13.96M | 8.10M | 8.12M | 1.47M | 7.26M | 16.29M |
| Cash, Cash Equivalents and Short-Term Investments | 12.36M | 7.02M | 7.15M | 1.17M | 6.44M | 15.19M |
| Total Debt | 78.00K | 107.00K | 278.00K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.70M | 2.67M | 3.64M | 4.47M | 1.10M | 938.00K |
| Stockholders Equity | 11.27M | 5.42M | 4.48M | -3.00M | 6.16M | 15.35M |
Cash Flow | ||||||
| Free Cash Flow | -11.30M | -10.97M | -9.14M | -10.26M | -8.81M | -5.93M |
| Operating Cash Flow | -11.30M | -10.97M | -9.13M | -10.26M | -8.81M | -5.92M |
| Investing Cash Flow | 0.00 | -2.00K | -12.00K | 2.03M | -2.03M | -15.00K |
| Financing Cash Flow | 9.08M | 10.85M | 15.12M | 5.01M | 42.00K | 19.33M |
RenovoRx Technical Analysis
Neutral
1.00
Price Trends
0.94
Negative
0.94
Negative
1.00
Negative
Market Momentum
-0.02
Negative
50.38
Neutral
63.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNXT, the sentiment is Neutral. The current price of 1 is above the 20-day moving average (MA) of 0.86, above the 50-day MA of 0.94, and above the 200-day MA of 1.00, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.38 is Neutral, neither overbought nor oversold. The STOCH value of 63.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RNXT.
RenovoRx Risk Analysis
RenovoRx disclosed 73 risk factors in its most recent earnings report. RenovoRx reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
RenovoRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $461.00M | -2.41 | -22.51% | ― | 1199.64% | 30.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $39.71M | -2.73 | -138.61% | ― | 520.42% | 16.12% | |
45 Neutral | $25.28M | -3.58 | -191.12% | ― | ― | 38.53% | |
44 Neutral | $34.04M | -4.61 | -10.61% | ― | ― | 70.83% | |
44 Neutral | $28.99M | -1.76 | 9999.00% | ― | ― | ― | |
44 Neutral | $104.45M | -1.72 | -59.89% | ― | ― | 44.08% |
* Healthcare Sector Average
RNXT
RenovoRx
0.88
-0.31
-25.97%
OVID
Ovid Therapeutics
2.47
2.19
766.67%
GRCE
Grace Therapeutics
2.20
-0.75
-25.42%
JSPR
Jasper Therapeutics
0.90
-3.87
-81.07%
NRSN
Neurosense Therapeutics Ltd.
0.82
-0.70
-46.05%
PEPG
PepGen Inc.
1.51
0.04
2.72%
RenovoRx Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial
Positive
Mar 30, 2026
RenovoRx reported its full-year 2025 results on March 30, 2026, highlighting $1.1 million in RenovoCath revenue in its first full year of commercialization and growing adoption at 12 U.S. cancer centers, with 21 more in the pipeline. The company c...
Business Operations and StrategyPrivate Placements and Financing
RenovoRx Raises $10 Million in Oversubscribed Private Placement
Positive
Mar 23, 2026
On March 17, 2026, RenovoRx entered into securities purchase agreements for an oversubscribed private placement of common stock, pre-funded warrants and milestone-based warrants with institutional investors and company insiders, closing on March 2...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.